Lixisenatide: difference between revisions
Diff·revision 3 → 4·00:06, 10 Nov 2024
Difference between revision 3 and revision 4 of Lixisenatide. 2 lines changed; the page grew by 276 bytes.
| Revision 3 — 01:50, 19 Oct 2024 AnalyticalAnnie (talk) convert the substitution list to a table so the analogues line up 1,771 bytes ±0 | Revision 4 — 00:06, 10 Nov 2024 DulaglutideDug (talk) add the peptide length to the infobox 2,047 bytes +276 | ||
|---|---|---|---|
| 11 | Its pharmacological profile emphasises postprandial glycaemic control through pronounced delay of [[Gastric emptying|gastric emptying]], an effect that does not attenuate as it does with continuously present long-acting agonists.{{r|drucker2018}} | 11 | Its pharmacological profile emphasises postprandial glycaemic control through pronounced delay of [[Gastric emptying|gastric emptying]], an effect that does not attenuate as it does with continuously present long-acting agonists.{{r|drucker2018}} |
| 12 | 12 | ||
| + | 13 | The ELIXA trial randomised people with type 2 diabetes and a recent acute coronary syndrome and reported no difference in cardiovascular outcomes. That neutral result is one of the principal reasons cardiovascular benefit is not treated as a class property.{{r|pfeffer2015}} | |
| + | 14 | ||
| 13 | == Pharmacology == | 15 | == Pharmacology == |
| 14 | Like exenatide, lixisenatide carries glycine at position 2 of the exendin scaffold and is therefore not a substrate for [[Dipeptidyl peptidase-4|DPP-4]]. Its half-life of about three hours nonetheless requires daily dosing, since renal clearance dominates once proteolysis is removed.{{r|drucker2018}} | 16 | Like exenatide, lixisenatide carries glycine at position 2 of the exendin scaffold and is therefore not a substrate for [[Dipeptidyl peptidase-4|DPP-4]]. Its half-life of about three hours nonetheless requires daily dosing, since renal clearance dominates once proteolysis is removed.{{r|drucker2018}} |